Group 1 - The Hong Kong stock market for innovative drug concept stocks is showing strength, with companies like BeiGene rising over 6%, 3SBio increasing over 3%, and WuXi Biologics up over 2% [1] - Several Hong Kong innovative drug-related ETFs have also increased by over 2% due to market influences [2] - Specific ETFs such as the Hong Kong Innovative Drug ETF T+0 and the Hong Kong Innovative Drug Selected ETF have reported gains of 3.24% and 2.47% respectively [3] Group 2 - Upcoming global conferences, including the World Conference on Lung Cancer (WCLC) in September and the European Society for Medical Oncology (ESMO) in October, will showcase research results from domestic innovative drugs [3] - Notable products to be presented include AK112 from CanSino Biologics and DB-1311 from InnoCare Pharma, highlighting the increasing competitiveness of domestic innovative drugs in clinical data and progress [3] - The trend of innovative drugs going global is strengthening as domestic companies enhance their clinical capabilities [3]
港股创新药概念股走强，多只港股创新药相关ETF涨超2%
Mei Ri Jing Ji Xin Wen·2025-09-02 02:28